Suppr超能文献

肺纤维化相关的 MUC5B 启动子多态性不影响系统性硬化症间质性肺炎的发生。

The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis.

机构信息

School of Public Health, University of Colorado Denver, Aurora, CO.

Vanderbilt University School of Medicine, Nashville, TN.

出版信息

Chest. 2012 Dec;142(6):1584-1588. doi: 10.1378/chest.12-0110.

Abstract

BACKGROUND

More than 80% of patients with systemic sclerosis (SSc) develop lung involvement, most commonly interstitial pneumonia (IP). We recently identified a common variant in the promoter region of MUC5B (rs35705950) that has a significant effect on the risk of developing both familial and sporadic forms of IP. We hypothesized that this MUC5B promoter polymorphism is also associated with IP in subjects with SSc.

METHODS

We examined the minor allele frequency of the MUC5B polymorphism among 231 subjects with SSc, 109 with IP, and 122 without IP. IP diagnosis was confirmed by HRCT imaging and defined as the presence of reticular infiltrates and/or honeycomb cysts. FVC and diffusing capacity of the lung for carbon monoxide (Dlco) were also assessed.

RESULTS

We found no association between IP and the MUC5B polymorphism among subjects with SSc (OR = 1.1, P = .80). The frequencies of the MUC5B polymorphism among subjects with SSc with IP (10.6%) and without IP (9.4%) were similar to the frequency observed in a population of unaffected control subjects (9.0%). In secondary analyses, we found the MUC5B polymorphism was not significantly associated with either FVC (P = .42) or Dlco (P = .06). No association with SSc-associated IP was found even when we used a more conservative definition of IP (FVC ≤ 70% and evidence of reticulations or honeycombing vs SSc FVC > 70% and no evidence of reticulation or honeycombing).

CONCLUSIONS

Although SSc-associated IP is clinically, radiologically, and histologically similar to other forms of IP, it appears to have distinct genetic risk factors. This study highlights the genetic and phenotypic heterogeneity of IP in general.

摘要

背景

超过 80%的系统性硬化症(SSc)患者会发生肺部受累,最常见的是间质性肺炎(IP)。我们最近发现 MUC5B 启动子区域的一个常见变体(rs35705950)对家族性和散发性 IP 的发病风险有显著影响。我们假设该 MUC5B 启动子多态性与 SSc 患者的 IP 也有关。

方法

我们检测了 231 例 SSc 患者、109 例 IP 患者和 122 例无 IP 患者中 MUC5B 多态性的次要等位基因频率。IP 诊断通过 HRCT 成像确认,并定义为存在网状浸润和/或蜂窝状囊肿。还评估了 FVC 和肺一氧化碳弥散量(Dlco)。

结果

我们未发现 MUC5B 多态性与 SSc 患者的 IP 之间存在关联(OR = 1.1,P =.80)。在有 IP 的 SSc 患者(10.6%)和无 IP 的 SSc 患者(9.4%)中,MUC5B 多态性的频率与未受影响的对照人群中观察到的频率相似(9.0%)。在二次分析中,我们发现 MUC5B 多态性与 FVC (P =.42)或 Dlco (P =.06)均无显著相关性。即使我们使用更严格的 IP 定义(FVC ≤ 70%和存在网状或蜂窝改变,与 SSc FVC > 70%和无网状或蜂窝改变),也未发现 MUC5B 多态性与 SSc 相关的 IP 相关。

结论

尽管 SSc 相关的 IP 在临床上、影像学上和组织学上与其他形式的 IP 相似,但它似乎有独特的遗传危险因素。本研究强调了 IP 的遗传和表型异质性。

相似文献

3
A common MUC5B promoter polymorphism and pulmonary fibrosis.
N Engl J Med. 2011 Apr 21;364(16):1503-12. doi: 10.1056/NEJMoa1013660.
4
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis.
Semin Arthritis Rheum. 2020 Oct;50(5):963-967. doi: 10.1016/j.semarthrit.2020.06.003. Epub 2020 Jun 16.
5
Interaction between the promoter polymorphism and mucin expression: is there a difference according to ILD subtype?
Thorax. 2020 Oct;75(10):901-903. doi: 10.1136/thoraxjnl-2020-214579. Epub 2020 Jun 24.
7
Effect of Muc5b promoter polymorphism on disease predisposition and survival in idiopathic interstitial pneumonias.
Respirology. 2016 May;21(4):712-7. doi: 10.1111/resp.12728. Epub 2015 Dec 24.
8
MUC5B promoter polymorphism and interstitial lung abnormalities.
N Engl J Med. 2013 Jun 6;368(23):2192-200. doi: 10.1056/NEJMoa1216076. Epub 2013 May 21.
9
MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.
N Engl J Med. 2018 Dec 6;379(23):2209-2219. doi: 10.1056/NEJMoa1801562. Epub 2018 Oct 20.

引用本文的文献

2
A comparative study of different types of connective tissue-associated interstitial lung disease.
BMC Med Imaging. 2025 Apr 7;25(1):109. doi: 10.1186/s12880-025-01655-8.
3
Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine.
Am J Respir Crit Care Med. 2024 Aug 15;210(4):401-423. doi: 10.1164/rccm.202401-0238SO.
4
Clinical characteristics of patients with connective tissue disease-related interstitial lung disease: a retrospective analysis.
Clin Rheumatol. 2024 May;43(5):1693-1701. doi: 10.1007/s10067-024-06926-3. Epub 2024 Mar 9.
9
Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases.
Drugs Context. 2021 Jan 15;10. doi: 10.7573/dic.2020-9-1. eCollection 2021.

本文引用的文献

1
A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis.
N Engl J Med. 2011 Apr 21;364(16):1576-7. doi: 10.1056/NEJMc1013504.
2
A common MUC5B promoter polymorphism and pulmonary fibrosis.
N Engl J Med. 2011 Apr 21;364(16):1503-12. doi: 10.1056/NEJMoa1013660.
4
Imaging lung disease in systemic sclerosis.
Curr Rheumatol Rep. 2010 Apr;12(2):156-61. doi: 10.1007/s11926-010-0095-0.
5
Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus.
Nat Genet. 2010 May;42(5):426-9. doi: 10.1038/ng.565. Epub 2010 Apr 11.
9
Systemic sclerosis: a prototypic multisystem fibrotic disorder.
J Clin Invest. 2007 Mar;117(3):557-67. doi: 10.1172/JCI31139.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验